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Supplementary Table S1: Factor H levels 








Pedigree A (CFH C192F) 
III:2 Affected G/T 198a 
IV:1 Affected G/T 265 
IV:2 Affected G/T 294 
IV:3 Unaffected G/G 365 
IV:4 Affected G/T 252 
IV:5 Affected G/T 186a 
IV:6 Affected G/T 207a 
IV:7 Unaffected G/G 312 
Pedigree B (CFH IVS6+1G>A) 
II:1 Affected G/A 147a 
II:2 Affected G/A 191a 
Pedigree C (CFH R175P) 
II:1 Affected G/C 205a 
II:2 Affected G/C 193a 
Pedigree D (CFH R127H) 
II:1 Affected G/G 541 
II:2 Affected G/A 172a 
III:1 Affected G/A 271 
III:2 Unaffected G/G 493 
 
aBelow range of serum Factor H levels measured in controls; minimum level measured 









Supplementary Figure S1: Quantification of Factor H secreted into the supernatant 
 
The wild type and Factor H (FH) variant (C192F) were recombinantly expressed in 293T cells employing two separate 
transfections. The quantity of wild type and variant protein was determined by ELISA.  
(a) In the first transfection as shown, the mean concentration (shown as mean ± standard deviation) of wild type FH 
secreted into the supernatant was 52 µg/ml (± 7.1) and the mean concentration of FH C192F variant secreted was 
19 µg/ml (± 2.6); i.e. the FH variant was secreted at 36% compared to wild type. 
(b) In the second transfection as shown, the mean concentration of wild type FH secreted was 198 µg/ml (± 29.8) and 
the mean concentration of FH C192F variant secreted was 114 µg/ml (± 15.9); i.e. the FH variant was secreted at 










































































Supplementary Figure S2: Functional evaluation of a Factor H mutation: Cofactor activity 
 
C3b is resistant to inactivation by Factor H (FH) variant R175P. We incubated the FH proteins (wild type or R175P variant) 
at physiological salt concentration with C3b and Factor I (FI) at 37°C for 30 min. The reaction was stopped by addition of 
3x reducing buffer. After electrophoresis and transfer to a nitrocellulose membrane, Western blots were developed using 
goat anti-human C3 polyclonal antibody (a). Bands were quantified using densitometry (b). There was minimal, if any, 
detectable cleavage of C3b by FH R175P while the two positive controls (lanes 2 and 3) cleaved ~70% of the α’-chain of 
C3b.  
 
Lane 1, C3b alone (10 ng, negative control); lane 2, C3b (10 ng) with purified FH (200 ng) and FI (20 ng); lane 3, C3b (10 
ng) incubated with wild type FH (200 ng, recombinantly produced in our lab) and FI (20 ng); lane 4, C3b (10 ng) incubated 
with R175P FH variant (200 ng, recombinantly produced in our lab) and FI (20 ng). Purified C3b, FH, and FI obtained from 
Complement Technologies, Inc. M
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Supplementary Figure S3: Distribution of genetic risk scores 
    = controls (Clinical Age-Related Maculopathy Staging [CARMS]23 grade 1);     = AMD 
cases (CARMS grades 3B, 4, and 5); vertical black line indicates maximized sum of 
sensitivity and specificity threshold = 0.874. 
